Following an August 2025 CRL that raised no safety or manufacturing concerns, Saol provided additional survival analyses of existing clinical data to address FDA requirements without embarking on a ...
Shionogi’s oral main protease inhibitor Xocova (ensitrelvir) is now available in the US to reduce the risk of symptomatic ...
For patients with obstructive sleep apnea (OSA), hypoglossal nerve stimulation (HGNS) is associated with variable but potential long-term cardiovascular benefits, according to a study published online ...
"[These findings] strengthen the evidence that early-life PFAS exposure may have lasting effects on intestinal health." HealthDay News — Exposure to per- and polyfluoroalkyl substances (PFAS), or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results